​

Mineralys Therapeutics Stock (NASDAQ:MLYS)

ForecastOwnershipFinancialsChartTranscripts
Mineralys Therapeutics by TradingView

Previous Close

$36.73

52W Range

$8.24 - $47.65

50D Avg

$41.09

200D Avg

$23.16

Market Cap

$2.40B

Avg Vol (3M)

$1.48M

Beta

0.40

Div Yield

-

MLYS Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

51

IPO Date

Feb 10, 2023

Website

MLYS Performance

MLYS Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-192.40M$-84.66M$-31.48M
Net Income$-177.81M$-71.90M$-29.80M
EBITDA$-192.40M$-84.66M$-31.48M
Basic EPS$-3.66$-1.99$-0.73
Diluted EPS$-3.66$-1.99$-0.73

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 25Nov 10, 25 | 4:30 PM
Q2 25Aug 13, 25 | 4:30 PM
Q1 25May 12, 25 | 4:30 PM

Peer Comparison

TickerCompany
IDYAIDEAYA Biosciences, Inc.
ADPTAdaptive Biotechnologies Corporation
RXRXRecursion Pharmaceuticals, Inc.
APLSApellis Pharmaceuticals, Inc.
CPRXCatalyst Pharmaceuticals, Inc.
BEAMBeam Therapeutics Inc.
CDTXCidara Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
ZLABZai Lab Limited
SRRKScholar Rock Holding Corporation